Lodoxamide tromethamine

Research use only, not for human use.

Lodoxamide tromethamine is a mast cell stabilizer with anti-allergic properties and can be used in studies about the treatment of asthma and allergic conjunctivitis.

Lodoxamide tromethamine is a mast cell stabilizer with anti-allergic properties and can be used in studies about the treatment of asthma and allergic conjunctivitis.(In Vitro):In purified rat peritoneal mast cells, Lodoxamide tromethamine inhibits ionophore-induced 45Ca influx with associated histamine release. Lodoxamide tromethamine significantly and dose-dependently inhibits the chemotactic response of eosinophils to fMLP and to IL-5. Lodoxamide tromethamine strongly inhibits the release of eosinophil peroxidase after IgA-dependent activation and inhibits the release of eosinophil cationic protein and eosinophil-derived neurotoxin to a lesser extent.(In Vivo):In Ascaris-sensitized anesthetized rhesus monkeys, Lodoxamide tromethamine significantly inhibits the increased respiratory frequency and decreased tidal volume induced by antigen challenge. The addition of Lodoxamide tromethamine to Euro-Collins or University of Wisconsin solution increases oxygenation, decreases microvascular permeability, and increases compliance thereby decreasing lung reperfusion injury.

lodoxamide inhibits compound 48/80-induced histamine release and ionophore-induced 45Ca influx with associated histamine release in purified rat peritoneal mast cells.

Lodoxamide has been demonstrated to have cromolyn-like activity when studied in the rat peritoneal mast cell assay (PCA) model3 and in Ascaris antigen-sensitized rhesus monkeys. When given intravenously, orally, or intrabronchially by aerosol, lodoxamide significantly inhibits the increased respiratory frequency and decreased tidal volume induced by antigen challenge in Ascaris-sensitized. anesthetized rhesus monkeys. Addition of lodoxamide tromethamine to Euro-Collins or University of Wisconsin solution results in a marked decrease in lung reperfusion injury as demonstrated by increased oxygenation, decreased microvascular permeability, and increased compliance. Patients treated with lodoxamide tromethamine demonstrate an improvement in daytime breathing difficulty, cough, sputum production, and sleep.

U-42585E

GPCR/G Protein

Histamine Receptor

ETV1

——

——

63610-09-3

553.91

C19H28ClN5O12

>98% (HPLC)

In Vitro:?H2O : ≥ 100 mg/mL (180.54 mM))

NC(CO)(CO)CO.NC(CO)(CO)CO.OC(=O)C(=O)Nc1cc(cc(NC(=O)C(O)=O)c1Cl)C#N

——

(-20℃)

With Ice Pack

≥ 2 years